EANS-Adhoc: SYGNIS Pharma AG announces strategic restructuring

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

29.10.2010

Ad-hoc

SYGNIS Pharma AG announces strategic restructuring

Heidelberg, 29 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard) announced today a comprehensive,
strategic restructure of the company, which will include significant
personnel and cost reductions. The process has been approved by the
Supervisory Board and will be executed immediately.

The purpose of the restructuring is to reduce SYGNIS´ long-term
cost-structure to maintain a strategic focus on the Company´s current
projects, including the clinical development of its lead compound
AX200 for the treatment of acute stroke, which is currently in a
phase II efficacy trial (AXIS 2).

The total number of employees will be reduced from 51 to 32 (an
equivalent of 21 Full Time Employees). The core pre-clinical and
clinical development teams will remain in place to complete ongoing
AX200 development work as well as research on the KIBRA pathway.
Relating to the restructuring, the Company expects a one-time total
expense of up to EUR 0.5 million, which will occur in full in the
fiscal year 2010/11. Additional non-cash related expenses of up to
EUR 2.5 million could occur with regard to an impairment of
intangible assets.

With the reduced cost-base and the current liquidity it is expected
that SYGNIS will have sufficient funds to support the completion of
the ongoing phase II efficacy study for AX200. In addition, the
Company has access to an equity-line by Yorkville Advisors, which
will further extend SYGNIS´ financial runway. The Board believes the
new structure of the Company should position it more favourably for
potential future strategic transactions.

For further information please contact:
SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |
|Vice President Operations/ General |
|Counsel |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas

Vice President Operations/ General

Counsel

+49 (0) 6221 454 812

franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade